Virtonomy has closed a Series A financing round raising more than five million euros. Companisto is the lead investor, and Bayern Kapital is supporting the company with a renewed and increased investment. The Munich-based company was founded in 2019. Startup develops a cloud-based platform that allows manufacturers of medical technology products to test their innovations on virtual patients.
The digital patient twins are based on realistic datasets and multiphysics simulations. This allows companies to conduct tests faster, more frequently, and in multiple iterations. Virtonomy thus reduces the development time of medical devices by up to 40 percent and cuts costs in the millions. In addition to individual tests, the platform also enables population analyses and complete virtual studies.
With the new capital, Virtonomy is accelerating its next growth phase. The company plans to further scale its platform internationally, obtain regulatory validation for the integration of virtual studies into real-world approval processes, and expand its global presence and team. CEO Simon Sunday puts the importance of financing into perspective:
"The Series A funding round enables us to implement the next stage of scaling: deeper regulatory integration, greater geographic reach, and a more powerful infrastructure for digital clinical trials."
Focus on scaling and regulation
Bavaria Capital Virtonomy has been accompanied since the Seed financing round in 2021. The investment focuses on reducing animal and human testing in clinical trials. According to investors, the platform addresses a bottleneck in medical technology: the high complexity and cost of traditional clinical trials.
Companisto also sees great potential. Investment Manager Robin Ghosh says:
“Virtonomy combines a clear technological advantage with an internationally scalable model. The potential impact on MedTech development is significant, and we see strong momentum for the next phase.”
Monika Steger, Managing Director of Bayern Kapital, adds:
“Virtonomy eliminates a key bottleneck in medical technology. Its ability to reduce complexity, costs, and the need for physical studies enables the company to expand significantly worldwide.”
Currently, leading international medtech companies such as Medtronic, Johnson & Johnson, and Boston Scientific are already using the platform. This positions Virtonomy as a relevant player in the digital transformation of clinical trials, extending beyond its Munich location.
